Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1 Detailed results from the Phase III trial […]
Boehringer Ingelheim announced promising findings from the Phase III SYNCHRONIZE-2 trial, which evaluated the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults with obesity or overweight and type 2 diabetes (T2D). The trial met its primary endpoints of body weight change from baseline and a 5% or greater body weight reduction from baseline for both the treatment group and efficacy estimands.
After 76 weeks of treatment, the average weight loss in the survodutide group was 13.1%, significantly higher than the 3.1% loss observed in the placebo group (p < 0.0001). Additionally, 79.3% of those treated with survodutide achieved a body weight reduction of 5% or more, compared to 32.7% in the placebo group (p < 0.0001). The results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and published simultaneously in The New England Journal of Medicine.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
